An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases (NCT05732402)
An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Who can join: Review the eligibility criteria below.
Location: Investigational Site (523) — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- Investigational Site (523) — Phoenix, Arizona
- Investigational Site (501) — Phoenix, Arizona
- Investigational Site (524) — Tucson, Arizona
- Investigational Site (506) — Valencia, California
- Investigational Site (513) — Arvada, Colorado
- Investigational Site (512) — Orlando, Florida
- Investigational Site (525) — Tamarac, Florida
- Investigational Site (502) — Lawrenceville, Georgia
- The Johns Hopkins University School of Medicine — Baltimore, Maryland
- Investigational Site (503) — Boston, Massachusetts
- Washington University School of Medicine in St. Louis — St Louis, Missouri
- Investigational Site (509) — Newark, New Jersey
- Investigational Site (511) — Albany, New York
- Investigational Site (508) — Brooklyn, New York
- Investigational Site (518) — Bethlehem, Pennsylvania
- Investigational Site (118) — Colleyville, Texas
- Investigational Site (516) — Houston, Texas
- Investigational Site (526) — Irving, Texas
- Investigational Site (519) — Concord, New South Wales
- Investigational Site (515) — Saint Albans, Victoria
- Investigational Site (102) — Nedlands, Western Australia
- Investigational Site (191) — Caguas,
- Investigational Site (507) — Cheonan, Chungcheongnam-do
- Investigational Site (505) — Anyang-si, Gyeonggi-do
- Investigational Site (504) — Goyang-si, Gyeonggi-do
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Nephritis
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis — Palo Alto, California
- Daratumumab to Treat Active Lupus Nephritis — Rochester, Minnesota
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Birmingham, Alabama
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis — Glendale, Arizona
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis — Birmingham, Alabama
Explore by condition: All Lupus Nephritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.